Close Menu

PRINCETON, NJ--Bristol-Myers Squibb announced it will license the use of Acacia Biosciences' proprietary Genome Reporter Matrix, a technology to identify changes in the expression of thousands of genes in the presence of potential therapeutic compounds. Bristol-Myers Squibb will use the matrix to develop pharmaceutical compound profiles that can help researchers understand the therapeutic benefits and potential side effects of compounds, as well as identify novel targets for drug discovery.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Springer Nature announces €9,500 fee to make papers open-access in Nature and its family of journals.

Librarians have concluded that notebooks that belonged to Charles Darwin that were thought to have been lost were actually likely stolen, CNN reports.

An early SARS-CoV-2 alteration may have enabled it to spread more easily, according to the New York Times.

In PNAS this week: ultrarare variants contribute to aging-related hearing loss, telomeres of cells infected with herpesvirus, and more.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.